88 completed, 20 recruiting, 15 withdrawn, 12 unknown. 161 Phase 2, 34 Phase 1, 19 Phase 3.
Follow Marijuana Abuse: new trials by email Literature Review of Marijuana Abuse trials Research Report on Marijuana Abuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis Cannabidiol (CBD), Placebo - Schizophrenia Spectrum Disorders, Cannabis Use | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2050-01-01 | 2021-04-19 | |
| Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome | Phase 2 / Phase 3 | Not yet recruiting | Fenix Innovation Group | 40 | 2027-07-01 | 2026-09-09 |
| Inhaled Cannabis for Treatment of PTSD High THC Cannabis, Placebo cannabis - Post Traumatic Stress Disorder PTSD | Phase 2 | Not yet recruiting | Multidisciplinary Association for Psychedelic Studies | 320 | 2027-02-01 | 2026-08-11 |
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Varenicline as a Treatment for Cannabis Use Disorder Varenicline (Chantix), Placebo - Cannabis Abuse | Phase 2 | Not yet recruiting | Medical University of South Carolina | 224 | 2026-12-01 | 2026-08-25 |
| Trial of Tirzepatide for the Treatment of Cannabis Use Disorder Tirzepatide, Placebo - Cannabis Use Disorder | Phase 2 | Not yet recruiting | National Institute on Drug Abuse (NIDA) | 100 | 2026-11-15 | 2026-09-21 |
| An Investigation of Mechanisms That Underly Paranoia in Behaviour and Brain That Can Inform Clinical Diagnoses That Include Paranoid Symptoms. Low-dose THC administration via IV, High-Dose THC administration via IV, Saline administration via IV - None Volunteer | Phase 2 | Not yet recruiting | King's College London | 100 | 2026-11-01 | 2026-10-16 |
| Lemborexant for Cannabis Use Disorder Lemborexant 10mg, Placebo, Brief Behavioural Intervention - Cannabis Use Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Calgary | 28 | 2026-11-01 | 2026-09-22 |
| Tolerability and Efficacy of CBD Extract for RLS Treatment BRC-002, Placecbo - Restless Leg Syndrome | Phase 2 | Not yet recruiting | University of Colorado, Denver | 60 | 2026-11-01 | 2026-10-08 |
| Repeated Administration of Cannabis Varying in THC and CBD Cannabis - Cannabis | Phase 2 | Suspended | New York State Psychiatric Institute | 100 | 2026-10-01 | 2026-09-01 |
| A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users Cannabis, placebo - Cannabis | Phase 1 / Phase 2 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 80 | 2026-09-01 | 2025-12-22 |
| CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children Placebo, CBD Isolate, CBD CHE - Drug Resistant Epilepsy | Phase 2 | Not yet recruiting | University of Manitoba | 90 | 2026-07-27 | 2026-06-11 |
| Cannabidiol for Pain Relief of Patients With End-stage mCRPC Cannabidiol, Placebo - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Recruiting | Regionshospital Nordjylland | 58 | 2026-06-12 | 2026-09-16 |
| Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life Study Ecological Momentary Assessment (EMA) and Reality Monitoring tasks - Schizophrenia | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Charles Perrens, Bordeaux | 120 | 2026-06-01 | 2026-03-16 |
| Naturally Produced Cannabinoids for Neuroprotection From Concussion Broad spectrum cannabinoid formulation, Placebo gel capsule - Healthy | Phase 2 | Recruiting | University of Regina | 60 | 2026-06-01 | 2026-07-21 |
| Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder semaglutide, Placebo - Cannabis Use Disorder, Cannabis Use Disorders | Phase 2 | Recruiting | Anders Fink-Jensen, MD, DMSci | 100 | 2026-04-30 | 2026-05-14 |
| Pregnenolone as a Treatment for Cannabis Intoxication Cannabis, Pregnenolone 250 mg, Pregnenolone 500 mg - Cannabis Intoxication | Phase 2 | Recruiting | Johns Hopkins University | 20 | 2026-04-24 | 2026-09-29 |
| Cannabis (THC vs. CBD) in Multiple Sclerosis THC, CBD - Multiple Sclerosis | Phase 2 | Recruiting | University of Calgary | 30 | 2025-12-05 | 2026-09-15 |
| Oral and Topical Phytocannabinoids for Psoriasis Oral Cannabis Extract, Topical cannabis cream - Psoriasis Vulgaris | Phase 2 | Active not recruiting | Federal University of Latin American Integration | 37 | 2025-11-01 | 2026-09-24 |
| Warrior CARE: Cannabis Behavioral Health Tetrahydrocannabinol, Cannabidiol, Placebo - Post Traumatic Stress Disorder, Cannabis Use | Phase 1 / Phase 2 | Recruiting | Wayne State University | 500 | 2025-09-22 | 2026-08-07 |
Showing 20 of 161. Sign in to see all of them.
Pain (10) · Substance-Related Disorders (10) · Alcoholism (8) · Behavior, Addictive (7) · Anxiety Disorders (6) · Depression (6) · Multiple Sclerosis (6) · Neuralgia (6) · Marijuana Smoking (5) · Muscle Spasticity (5) · Psychotic Disorders (5) · Schizophrenia (5) · Agnosia (4) · Stress Disorders, Post-Traumatic (4)
Chemically-Induced Disorders (161) · Mental Disorders (158) · Substance-Related Disorders (151) · Nervous System Diseases (46) · Pathological Conditions, Signs and Symptoms (42) · Signs and Symptoms (37) · Neurologic Manifestations (36) · Behavior (26) · Central Nervous System Diseases (17) · Brain Diseases (14) · Neuromuscular Diseases (11) · Musculoskeletal Diseases (10) · Pain (10) · Immune System Diseases (9) · Muscular Diseases (9)
nabiximols (38) · Dronabinol (25) · Cannabidiol (24) · Medical Marijuana (6) · Sugars (5) · Acetylcysteine (3) · Atomoxetine Hydrochloride (3) · Buspirone (3) · Ethanol (3) · Motivational Interviewing (3) · Varenicline (3) · nabilone (3) · Aprepitant (2) · Baclofen (2) · Bupropion (2)
New York State Psychiatric Institute (18) · Medical University of South Carolina (11) · University of Colorado, Denver (8) · University of California, San Diego (7) · Center for Medicinal Cannabis Research (6) · Johns Hopkins University (6) · National Institute on Drug Abuse (NIDA) (6) · The Scripps Research Institute (5) · Mclean Hospital (4) · Boston Children's Hospital (3) · Brown University (3) · Centre hospitalier de l'Université de Montréal (CHUM) (3) · University of Manitoba (3) · Yale University (3) · Aelis Farma (2)
United States (101) · Canada (19) · Israel (7) · Denmark (5) · Australia (3) · Netherlands (3) · Poland (3) · Brazil (2) · Germany (2) · United Kingdom (2) · Argentina (1) · Czechia (1) · France (1) · Hong Kong (1) · Italy (1)
Barbara J Mason, Ph.D. (3) · Frances R Levin, M.D. (3) · Kevin M Gray, MD (3) · Kevin P Hill, MD, MHS (3) · Margaret Haney, Ph.D. (3) · Aimee L McRae, PharmD (2) · Aimee McRae-Clark, PharmD (2) · Barbara J. Mason, Ph.D. (2) · Claudia Campbell, PhD (2) · Didier Jutras-Aswad, MD,MS (2) · Fred Konikoff, professor (2) · Jane Metrik, PhD (2) · John J Mariani, MD (2) · John R Knight, MD (2) · Nathaniel M Schuster, MD (2)
PMID 31527291, PMID 34173005, PMID 34532852, PMID 12648025, PMID 15094417, PMID 16223067, PMID 16317825, PMID 17063973, PMID 17355521, PMID 17566383, PMID 17916224, PMID 18182254, PMID 18728826, PMID 19587829, PMID 19883531, PMID 19896326, PMID 20076976, PMID 20576364, PMID 21049267, PMID 21397626, PMID 21865014, PMID 22076835, PMID 22373942, PMID 22795046, PMID 22879754, PMID 22921474, PMID 23141881, PMID 23188041, PMID 23648372, PMID 23831756, PMID 24447885, PMID 25220020, PMID 26011657, PMID 26144593, PMID 26257143, PMID 26883879, PMID 27089154, PMID 27403414, PMID 28270105, PMID 28349233, PMID 28782982, PMID 29457671, PMID 29489073, PMID 29672090, PMID 29689485, PMID 30049223, PMID 30528676, PMID 30554828, PMID 30615854, PMID 32178232
P50DA009236 (4), K23DA015440 (2), P60DA005186 (2), R01DA025044 (2), R01DA030988 (2), U54DA037842 (2), 2009 (1), 2018 (1), 2023 (1), 2025 (1), I01CX002357 (1), K12DA000357 (1), K23DA021209 (1), K23DA045080 (1), K99DA029115 (1)